Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05637879 · ClinicalTrials.gov registry record · Phase 2
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
A Phase 2 study of PTSD, sponsored by White River Junction Veterans Affairs Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT05637879 is a Phase 2 study of PTSD that is actively recruiting participants, run by White River Junction Veterans Affairs Medical Center. The registered enrollment target is 92 participants, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05637879, a Phase 2 study of PTSD, is actively recruiting participants, sponsored by White River Junction Veterans Affairs Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Glecaprevir/pibrentasvir
Study Locations (1)
Vermont
- White River Junction VAMC - White River Junction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05637879
The ClinicalTrials.gov registry entry for NCT05637879 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (69% lower). The listed sponsor is White River Junction Veterans Affairs Medical Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05637879 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.
Frequently Asked Questions
What is clinical trial NCT05637879 about?
NCT05637879 is a clinical study titled "Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder". A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infectio...
What is the current status of trial NCT05637879?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2023-12-18. Estimated completion is 2026-09-30.
What conditions does trial NCT05637879 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT05637879?
The interventions under investigation include: Placebo (OTHER), Glecaprevir/pibrentasvir (DRUG).
Who is sponsoring clinical trial NCT05637879?
This trial is sponsored by White River Junction Veterans Affairs Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05637879 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
-
Intranasal Insulin for Posttraumatic Stress Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.